🟠 Moderate Evidence
A drug combination approved for treating moderate-to-severe nausea and vomiting in pregnancy (NVP) remains inconsistently available across England’s National Health Service, despite clinical evidence supporting its efficacy and safety. Investigation by BBC News reveals that access to diclegis—a combination of pyridoxine (vitamin B6) and doxylamine succinate—varies significantly by region, leaving pregnant patients without reliable access to a medication their clinicians may recommend.
Key takeaways
- Diclegis (pyridoxine and doxylamine) is approved by regulatory authorities for pregnancy-related nausea but faces inconsistent NHS availability
- Regional variation in formulary decisions means some trusts fund the medication while others do not, creating postcode disparities
- Pregnant patients may face out-of-pocket costs or be denied access despite clinical need, raising equity and patient safety concerns
NHS Formulary Access Variability: The Postcode Problem
Regional inconsistency in diclegis funding decisions across English NHS trusts, creating patient access disparities
Source: BBC investigation, 2024 | Illustrative regional variation | Georgian Medical Journal News
The Clinical Case: Safety and Evidence
Diclegis has been used internationally for decades to treat moderate-to-severe NVP, a condition that affects 60–80% of pregnant women and can significantly impair quality of life. The medication combines doxylamine (an antihistamine) with pyridoxine (vitamin B6) at doses studied in pregnancy. Regulatory review by the FDA and European Medicines Agency determined the combination to be safe and effective for maternal and fetal health when used as directed.
Despite this regulatory approval, clinical access remains constrained, forcing many NHS patients to either tolerate severe symptoms or pay privately. This disconnect between evidence and formulary policy raises questions about how NHS funding decisions are made for maternal medications.
Postcode Lottery: Regional Variation in Access
The BBC investigation revealed that diclegis funding decisions differ markedly between NHS regions and trusts. Some integrated care boards (ICBs) include the drug on their formulary, meaning pregnant patients can access it through their GP or maternity services. Others require patients to demonstrate failed treatment with alternatives first. Still others do not cover it at all, leaving the cost entirely to patients.
This variation creates a postcode lottery that contradicts NHS principles of equitable access. A pregnant woman living in one region may receive free diclegis while her counterpart in another cannot, despite identical clinical need. The result is differential access based on geography rather than clinical evidence.
Access to diclegis, a clinically approved pregnancy nausea medication, varies significantly by NHS region, with some trusts covering the cost and others leaving patients to pay privately—creating postcode disparities in maternal healthcare.
— BBC News investigation, 2024
Funding Constraints and Decision-Making Opacity
Formulary decisions at the NHS trust level are typically guided by cost-effectiveness assessments and budget constraints, but transparency about how diclegis was evaluated varies. Some clinicians and patient advocates argue that cost-benefit analyses may not adequately weigh the maternal quality-of-life benefits of effective NVP treatment against the medication’s modest price.
When pregnant women with severe nausea cannot access approved medication, they may experience prolonged suffering, malnutrition, and dehydration—complications that could themselves incur NHS costs through additional healthcare visits and management. The economic case for formulary inclusion may thus be stronger than individual trust budgets suggest.
Implications for Maternal Healthcare Equity
This access disparity highlights a broader challenge in NHS quality and equity standards. Pregnant patients are among the most vulnerable populations in healthcare, and maternal conditions like moderate-to-severe NVP warrant consistent, evidence-based treatment. When access depends on postcode rather than clinical need, equity principles are compromised.
Patient advocacy groups have called for NHS England to issue guidance standardizing diclegis access decisions across all trusts. Such national guidance would ensure consistent application of clinical evidence and reduce the current patchwork of regional policies. Without intervention, the current situation perpetuates healthcare inequality for pregnant women.
What this means
Frequently asked questions
Is diclegis safe in pregnancy?
Yes. Regulatory agencies including the FDA and EMA have determined that diclegis is safe and effective for treating moderate-to-severe nausea and vomiting in pregnancy. The drug has been used internationally for decades with established safety data.
Why do some NHS trusts not fund diclegis?
Formulary decisions typically reflect budget constraints and cost-effectiveness judgments made at the regional trust level. However, these decisions are often opaque, and some trusts may not have formally evaluated the medication. Advocacy for national guidance could standardize these decisions across the NHS.
What can pregnant women do if diclegis is not available on their NHS formulary?
Options include requesting an individual funding application through their local trust’s exceptional case panel, exploring private prescription options, or asking their clinician about alternative approved treatments. Patient advocacy groups recommend contacting NHS England regarding postcode lottery concerns.
As NHS trusts continue to navigate budget pressures, maternal healthcare must remain a priority. Standardizing access to evidence-based pregnancy medications like diclegis would strengthen maternal care equity and demonstrate commitment to supporting women’s health throughout pregnancy. The coming months will be critical in determining whether NHS leadership addresses this access disparity at a national level.
Source: BBC News: Why is pregnancy sickness drug not easily accessible to all?
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
